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The importance of the metabolic syndrome (MetS) in the pathogenesis of cardio-
vascular disease has increasingly been addressed. Recently, accumulating
epidemiological and clinical evidence has shown that MetS is associated with
increased risks for cardiovascular disease
1,2 and type 2 diabetes mellitus.
3,4 More
recently, MetS was found to be an independent predictor for cardiovascular
disease in hypertensive subjects.
5 Furthermore, several subsequent studies reported
that MetS was associated with the hypertension- related target organ damage
6-8
such as left ventricular hypertrophy and impaired arterial distensibility, suggesting
MetS with subclinical organ damage as a mediator of enhanced cardiovascular risks. 
The mechanisms underlying the association of MetS in hypertension with the
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Purpose: In the present study, we tested whether the presence of metabolic syndrome (MetS) would worsen the
features of inflammation, plasma omega 3 fatty acid levels and antioxidant potential in treated hypertensive
patients. Materials and Methods: Two groups were classified by the components of MetS: a reference group of
treated hypertensive subjects: hypertension (HTN) group (n = 39) and with more than two additional MetS
components: HTN with Mets group (n = 40). We further compared the parameters between HTN group and HTN
with MetS group. Results: The results showed that age (p < 0.001) and body mass index (BMI) (p < 0.001) were
significantly different between HTN group and HTN with MetS group. Age- and BMI-adjusted total radical
trapping antioxidant potential (TRAP) (p < 0.01) was significantly lower, whereas age- and BMI-adjusted CD (p <
0.05) and interleukin (IL) 6 (p < 0.05) were significantly higher in HTN with MetS group than in HTN group.
Moreover, HTN with MetS group had significantly lower levels of age- and BMI-adjusted plasma phospholipid
eicosapentaenoic acid (EPA) than HTN group (p < 0.05). On the other hand, the levels of age- and BMI-adjusted
intracellular cell adhesion molecule-1 (ICAM-1), adiponectin and high molecular weight (HMW)-adiponectin were
not significantly different between the groups. Conclusion: In conclusion, our results showed increased
inflammatory marker, reduced antioxidant potential and EPA levels in treated hypertensive patients in the presence
of MetS, suggesting the importance of changes of therapeutic lifestyle to modify the features of MetS.
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development of cardiovascular disease remain uncertain.





11 Given that hypertension, as a primary
part of MetS, is usually accompanied by other cardiome-
tabolic risk factors,
12 it is possible that the cardiovascular
risk profiles are greatly exaggerated in the presence of
underlying MetS in hypertension, thus possibly leading to
increased risks for cardiovascular morbidity and mortality. 
In the present study, we hypothesized that the presence
of MetS would result in unfavorable patterns for cardio-
vascular risk profiles in treated hypertensive patients. To
test this possibility, we evaluated the inflammatory markers
and antioxidant potential together with blood omega 3
fatty acid compositions which have emerged as a risk
factor for cardiovascular disease in hypertension with- or
without MetS.
Subjects 
One hundred thirty-five hypertensive patients who had been
diagnosed and treated at Yonsei Cardiovascular Center
participated in the present study. Subjects with any of the
following conditions were excluded from participation:
valvular heart disease, peripheral vascular disease, signifi-
cant systemic disease, history of inflammatory disease
and/or on anti-inflammatory medications, patient taking
aldosterone antagonists at the time of study enrollment,
clinically significant atrioventricular conduction distur-
bance, history of atrial fibrillation or other serious arrhy-
thmia, severe hypertension (> 210/130 mmHg) or serum
creatinine greater than 1.4 mg/dL. They underwent a brief
physical examination for measurement of seated blood
pressure using a sphygmomanometer with an appropriate
cuff. Two measurements were taken at least five minutes
apart and the mean value was used for analysis. Weight was
measured using a standard balance beam scale or an elec-
tronic scale and height was measured using a height rod of
a standard beam scale, or a wall-mounted stadiometer.
Body Mass Index (BMI) was calculated as weight in kg
divided by height in meters squared. Waist circumference
was measured twice to the nearest 0.1 cm with a flexible tape
measure at the level of the minimum circumference, usually
at the level of the navel. All patients gave written informed
consent, and the Institutional Review Board at the Yonsei
University Medical Center approved the study protocol. 
Classification of MetS
MetS was defined as three or more of the following abnor-
malities according to modified NCEP ATP III definition
(ATP III criteria and the WHO Western Pacific Region
obesity criteria)
13,14: 1) abdominal obesity, waist circum-
ference ≥ 90 cm in men, ≥ 80 cm in women; 2) hypertrigly-
ceridemia, ≥150 mg/dL; 3) high-density lipoprotein (HDL)-
cholesterol, < 40 mg/dL in men and < 50 mg/dL in women;
4) hypertension (systolic blood pressure ≥ 130 mmHg or
diastolic pressure ≥ 85 mmHg) or on anti-hypertensive
medication; 5) high fasting glucose, ≥ 110 mg/dL or under
treatment for diabetes.
Serum lipid profiles, glucose, insulin and HOMA
Fasting blood samples were taken, and serum cholesterol,
low-density lipoprotein (LDL)-cholesterol and HDL-choles-
terol were measured by enzymatic methods with commer-
cially available kits (Choongwae, Seoul, Korea). Serum
triglyceride levels were analyzed using a total glycerol test
kit (Roche, Basel, Switzerland). All determinants were
done on a Hitachi 747 auto-analyzer (Hitachi Ltd., Tokyo,
Japan). Fasting serum glucose concentrations were mea-
sured by the glucose oxidase method using a Beckman
Glucose Analyzer (Beckman Instruments, Irvine, CA, USA).
The fasting serum insulin level was measured with an immu-
noradiometric assay and a gamma counter (Hewlett Packard,
Meriden, CT, USA). We calculated homeostasis model of
insulin resistance (HOMA-IR) using the equation HOMA-
IR = fasting insulin (µU/mL) ×glucose (mmol/L)/22.5.
15
Conjugated dienes in LDL
Baseline LDL conjugated dienes (CD) were determined
according to Ahotupa, et al.
16 with little modification. One
hundred µL of plasma was added to 700 µL of heparin
citrate buffer (0.064 M trisodium citrate, 50,000 IU/L
heparin, pH 5.05), and the suspension was allowed to stand
for 10 min at room temperature. The insoluble lipoproteins
were then sedimented by centrifugation at 1,000 g for 10
min. The pellet was resuspended in 100 µl of 0.1 M Na-
phosphate buffer containing 0.9% NaCl (pH 7.4). Lipids
were extracted from 100 µL of LDL suspension by chloro-
form-methanol (2 : 1), dried under nitrogen, then redissolved
in cyclohexane and analyzed spectrophotometrically at 234
nm. Oxidation during the sample preparation was pre-
vented by adding ethylenediaminetetraacetic acid (EDTA). 
Plasma total radical trapping antioxidant potential 
(TRAP) 
TRAP was measured by a modification of the photometric
method according to Rice-Evans and Miller.
17 The method
for measuring antioxidant activity is based on the antioxi-
dants’ inhibition of absorbance of the radical cation, 2,2’-
azinobis (3-ethylbenzothiazoline 6-sulfonate) (ABTS
+).
The ABTS
+ radical cation was formed by the interaction of
ABTS
+ (150 µM) with ferrylmyoglobin radical species,
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generated by the activation of metmyoglobin (2.5 µM) with
H2O2 (75 µM). Ten µL of sample/buffer/Trolox-standard
were added to tubes containing 400 µL of phosphate
buffered saline (PBS) buffer, 20 µL of metmyoglobin and
400 µL of ABTS, and the contents were mixed by vortex-
ing. The reaction was initiated by addition of 170 µL of
H2O2. Absorbance was measured with a spectrophotometer
at 734 nm after 6 min of incubation. Values were expressed
as trolox equivalent antioxidant capacity (TEAC), which is
defined as mM concentration of Trolox antioxidant
capacity, determined by using a calibration curve.
Plasma phospholipid eicosapentaenoic acid and 
docosahexaenoic acid contents 
Total lipids were extracted according to the method of Folch,
et al., and the phospholipid fraction was isolated by using
thin-layer chromatography with hexane : diethyl ether :
acetic acid (80 : 20 : 2) development solvent. The phospho-
lipid fractions were then directly transesterified to prepare
fatty acid methyl esters (FAMEs) by the method of Lepage
and Roy.
18 The FAME of individual fatty acids of phos-
pholipids was separated on a gas chromatograph (model
6890, Agilent Technologies Inc, Palo Alto, CA, USA)
equipped with a capillary column (SP-2560; 100m, Supelco,
Bellefonte, PA, USA) as previously described.
19 Peak
retention times were identified by comparison with known
standard (37 component FAME mix, Supelco, Bellefonte,
PA; GLC37, NuCheck Prep, Elysian, MN, USA) and ana-
lyzed with the ChemStation software (Agilent Technol-
ogies). Plasma phospholipid levels of EPA and DHA were
expressed as the percentage of total fatty acids.
Assay of plasma IL-6, ICAM-1, adiponectin, and 
HMW-adiponectin
Plasma interleukin-6 (IL-6, R&D Systems, Minneapolis,
MN, USA), intercellular cell adhesion molecule-1 (ICAM-
1, R&D Systems, Minneapolis, MN, USA), adiponectin
(Linco Research, St. Charles, MO, USA) and high molecular
weight adiponectin (HMW-adiponetin, Linco Research, St.
Charles, MO, USA) were measured using an enzyme-linked
immunoassay according to manufacturer’s instructions. 
Statistical analysis
The Statistical Package for Social Science (SPSS; SPSS Inc,
Chicago, IL, USA) 12.0 software package was used for
statistical analysis. Data are presented as mean ± S.E. Each
variable was examined for normal distribution, and abnor-
mally distributed variables were log-transformed. Frequency
distributions were tested by χ 2 test among the groups.
General Linear Model (GLM) was used to test the differ-
ences of parameters between the groups after adjusting age
and BMI. p values < 0.05 were considered statistically
significant.
Of the 135 treated hypertensive subjects, 124 subjects were
RESULTS
Table 1.Baseline Characteristics and Serum Lipids and HOMA-IR of Subjects according to the Presence of MetS
HTN only (n = 39) HTN with MetS  (n = 40)
Age (yrs) 52.1 ± 1.5 58.5 ± 1.0*
Body mass index (kg/m
2) 23.2 ± 0.2  25.8 ± 0.4*
Male : Female
� 18 : 21 22 : 18
Systolic blood pressure (mmHg) 125.3 ± 2.1 131.0 ± 2.2
Diastolic blood pressure (mmHg) 80.4 ± 1.5 81.4 ± 1.5
Medical treatments
Diuretics (%) 10.5 14.6
β-blocker (%) 15.4 17.1
ACEI and / or ARB 46.2 41.5
Calcium channel blocker (%) 61.5 71.6
HOMA-IR 1.5 ± 0.3  3.5 ± 0.3*
Total cholesterol (mg/dL) 183.4 ± 4.4 184.5 ± 4.2
Triglyceride (mg/dL) 93.3 ± 4.7  216.0 ± 17.9*
LDL-cholesterol (mg/dL) 124.3 ± 4.6 116.4 ± 4.5
HDL-cholesterol (mg/dL) 59.5 ± 2.1  47.8 ± 1.6*
HOMA-IR, homeostasis model of insulin resistance; MetS, metabolic syndrome; HTN, hypertension; ACEI, angiotensin converting enzyme 
inhibitors; ARB, angiotensin II receptor blocker; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Values are mean ± SE.
*p < 0.001.
�χ 2test.Min-Jeong Shin, et al.
Yonsei Med J   http://www.eymj.org    Volume 50   Number 6   December 2009 760
available for the classification of MetS and further analyzed
for this study. Based on the criteria of MetS, two groups
were classified by the components of MetS: a reference
group of treated hypertensive subjects: HTN group (n =
39) and with more than two additional MetS components:
HTN with Mets group (n = 40), and we further compared
the parameters between HTN group and HTN with MetS
group. The proportions of patients taking these medica-
tions were similar between the groups (Table 1).
Table 1 describes baseline characteristics and clinical
parameters between HTN group and HTN with MetS
group. Age (p < 0.001) and BMI (p < 0.001) were signi-
ficantly different between the groups. Systolic and diastolic
blood pressure and gender distribution were not signifi-
cantly different. As expected, serum concentrations of TG
(p < 0.001) and HDL-cholesterol (p < 0.001) and the levels
of HOMA-IR (p < 0.001) were significantly different bet-
ween the groups. On the other hand, serum concentrations
of total cholesterol and LDL-cholesterol were similar
between the two groups. 
Table 2 compares LDL-CD, TRAP, phospholipid DHA
and inflammatory markers between the two groups.
Because age and BMI were significantly different between
the groups, we used the age- and BMI-adjusted values for
all analyses. The results showed that age- and BMI-adjusted
TRAP (p < 0.01) was significantly lower, whereas age- and
BMI-adjusted CD (p < 0.05) was significantly higher in
HTN with MetS group than in HTN group. On the other
hand, the levels of age- and BMI-adjusted ICAM-1, adipo-
nectin and HMW-adiponectin were not significantly
different between the groups. 
Moreover, HTN with MetS group had significantly
lower levels of age- and BMI-adjusted plasma phospho-
lipid EPA (p < 0.05) and significantly higher levels of age-
and BMI-adjusted IL-6 (p < 0.05) than in HTN group,
whereas no differences were found in DHA between the
two groups (Fig. 1). 
To examine the synergistic effects of MetS in hypertension
on cardiovascular risk profiles, we evaluated plasma LDL-
CD as a marker for lipid peroxidation, TRAP as a reflection
of antioxidant potential, inflammation (IL-6, ICAM-1,
total- and HMW- adiponectin) and plasma phospholipid
omega 3 fatty acid contents. Our results showed that the
levels of LDL-CD and IL-6 were increased whereas the
levels of TRAP and plasma phospholipid EPA were
decreased in hypertensive patients with MetS compared to
those in hypertensive patients. 
It is well demonstrated that increased oxidative stress
underlies the pathophysiology of hypertension by directly
influencing vascular wall cells
20 and oxidative stress has
been associated with the onset of cardiovascular complica-
tions in subjects with the metabolic syndrome.
21 Several
observational and experimental studies showed impaired
antioxidant systems with decreases in antioxidant capacity
and increases in lipid peroxidation in MetS,
22 which is
DISCUSSION
Table 2. Age- and BMI-adjusted Lipid Peroxidation, Inflammatory Markers and Plasma DHA Contents of 
Subjects according to the Presence of MetS
HTN only (n = 39) HTN with MetS (n = 40)
LDL-CD (µM) 3.0 ± 0.9 5.8 ± 0.8*
TRAP (mM) 1.38 ± 0.02  1.32 ± 0.01
�
Adiponectin (µg/mL) 8.99 ± 0.81 7.48 ± 0.78
HMW-Adiponectin (µg/mL) 4.43 ± 0.80 3.50 ± 0.78
DHA (% of total fatty acids) 3.18 ± 0.22 3.32 ± 0.21
BMI, body mass index; DHA, docosahexaenoic acid; MetS, metabolic syndrome; HTN, hypertension; LDL-CD, conjugated dienes in low-
density lipoprotein; TRAP, total radical trapping antioxidant potential; HMW, high molecular weight adiponectin.
Values are Mean ± S.E. All data presented are adjusted for age and BMI.
*p< 0.05.
�p< 0.01.
Fig. 1. Comparison of age- and BMI-adjusted levels of IL-6 and EPA between
hypertension group and hypertension with MetS group (*p < 0.05). BMI, body
mass index; IL-6, interleukin-6; EPA, eicosapentaenoic acid; MetS, metabolic
syndrome.consistent with our results. Hyperglycemia, a key compo-
nent of the MetS, might trigger oxidative stress by several
mechanisms either independently or associated with other
conditions.
23 It includes glucose auto-oxidation, advanced
glycated end product (AGE) formation, abnormal arachi-
donic acid metabolism and its coupling to cyclooxygenase
catalysis.
23 The enhanced lipid peroxidation and reduced
antioxidant potential in hypertension with MetS, shown in
the present study, can be explained, in part, through the
mechanisms mentioned above. Considering the athero-
genic effect of oxidative alterations in the atherosclerotic
process,
24 our results provide a possible mechanism which
links MetS in hypertension to increased cardiovascular risks. 
Inflammation has been established to be a major media-
tor of increased cardiovascular risks.
25 As evidenced by
elevations of circulating levels of C-reactive protein (CRP)
and several inflammatory cytokines including IL-6 and
tumor necrosis factor-α (TNF-α), chronic inflammation
has been associated with hypertension and MetS.
26,27 Con-
sistent with the earlier findings,
26,27 we observed in the
present study that plasma levels of IL-6 were significantly
higher in the hypertensive patients with MetS. Adiponec-
tin, a most abundant adipokine, is primarily released from
adipose tissue, and adipose tissue is believed to be an im-
portant mediator of oxidative stress and inflammation.
28 The
profound metabolic effects of adiponectin on glucose and
lipid metabolism provide an evidence to link obesity-related
chronic inflammation and atherosclerosis.
28,29 HMW-adi-
ponectin is a multimeric form of adipoenctin and has been
suggested as a more sensitive biomarker for insulin resistance
and abdominal adiposity than total adiponectin.
29 In con-
trast to the previous studies,
28-31 there were no significant
differences in total- and HMW-adiponectin levels between
the groups. This may be attributed, in part, to the study
population with narrow range in BMI (mean 24.6 kg/m
2,
20.0-29.8) in the present study. However, we found gender-
specific differences in total- and HMW adiponectin between
hypertension group and hypertension with MetS group. In
females, plasma levels of total- and HMW adiponectin
were significantly lower in hypertension with MetS group
than hypertension group, but not in males (data not shown).
Also, the effect of MetS in hypertension on the levels of
TRAP was mainly derived from females (data not shown).
Our results partly support that MetS may have different
relative importance for cardiovascular disease according to
gender, and that the prognostic impact of MetS is better in
females than in males.
2,6,32
Emerging evidence showed that omega-3 fatty acids
(EPA and DHA) have a variety of beneficial effects on
blood pressure, platelet aggregation, inflammatory responses
and vasodilation as well as lipid and lipoprotein metabo-
lism.
33 Furthermore, omega 3 fatty acids were found to
protect cardiovascular morbidity and mortality,
34,35 suggest-
ing as an emerging risk factor for cardiovascular disease.
The mechanisms by which omega 3 fatty acids exhibit
cardioprotective effects include that they alter membrane
physical characteristics and the activity of membrane-
bound proteins.
36 Furthermore, they can interact with ion
channels and also act as ligands for several nuclear tran-
scription factors.
36 The major finding in this study was that
plasma phospholipid EPA content was significantly lower
in hypertensive patients with MetS than that in hypertensive
patients, whereas no difference was observed in DHA.
Given that EPA is known to inhibit the production of proin-
flammatory eicosanoids more efficiently than DHA,
37 it
may modulate inflammatory conditions, oxidative stress
accompanied by reduced antioxidant potential, which was
not experimentally proved in this study. However, only
plasma phosholipid EPA, but not DHA, was slightly
reduced, therefore, it is also possible to consider potential
metabolic alterations. EPA may in part originate from retro-
conversion of DHA in the peroxisome which requires
partial β-oxidation.
38 Thus, diminished levels of EPA and
concomitantly enhanced DHA may occur under conditions
of reduced peroxisomal β-oxidation in the MetS. Further
experimental studies are needed to elucidate the mechanism
for these relationships described in this study.
The main limitations of this study are small sample size
and cross-sectional setting, thus making it hard to draw
causality. Also, we could not exclude the possibility that
lack of nutritional information on fatty acids and fish con-
sumption might confound the results. Nevertheless, our
results extended several previous studies by showing
synergistic effects of MetS in hypertension on inflammation
and oxidative stress. Furthermore, we found decreased
plasma phospholipid EPA in hypertensive patients with
MetS, suggesting possible impact of MetS on inflam-
matory response in hypertension.
To conclude, our results showed increased inflammatory
marker, reduced plasma phospholipid EPA content and
reduced antioxidant potential in treated hypertensive patients
in the presence of MetS. Considering that blood and tissue
omega 3 fatty acids are the reflections of dietary intakes,
36
our results suggest the importance of changes of thera-
peutic lifestyle to modify the features of MetS. Intensive
nutritional program needs to be encouraged in these hyper-
tensive patients with MetS in clinical settings. 
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